Natco Pharma announces launch of first generic of top selling cancer drug Revlimid

Natco Pharma announces launch of first generic of top selling cancer drug Revlimid

By, Admin 8 March 2022

Revlimid had annual sales of $2.3 billion as of December 2021, according to IQVIA data. The generic version of Revlimid will be available in 5mg, 10mg, 15mg, and 25mg strengths. The announcement came after market hours. The Shares of Natco Pharma 2.98% to close at Rs 844.30 on BSE on Monday, the benchmark Sensex fell 2.74% to end at 52,842.75 points. Natco Pharma along with its marketing partner Arrow International - an affiliate of Israeli-drug maler Teva Pharmaceutical Industries on Monday announced the launch of the first generic version of Celgene's (now acquired by Bristol Myers Squibb) top selling cancer drug Revlimid (lenalidomide capsules) in in the US market. according to IQVIA data. The generic version of Revlimid will be available in 5mg, 10mg, 15mg, and 25mg strengths The announcement came after market hours. The Shares of Natco Pharma 2.98% to close at Rs 844.30 on BSE on Monday, the benchmark Sensex fell 2.74% to end at 52,842.75 points. Natco is heavily banking on the Revlimid generic to push its sales and profits. Natco, along with its marketing partner Arrow International previously settled the Paragraph IV litigation related to the Revlimid with Celgene, now part of BristolMyers Squibb in 2015. Lenalidomide capsules are prescribed in adults for the treatment of multiple myeloma in combination with the medicine dexamethasone, certain myelodysplastic syndromes, and mantle cell lymphoma following specific prior treatment.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!